2x founder

Nizar Batada

Cancer Immunology | Translational Science | Computational Genomics

Co-founder

Eugit Therapeutics· Summer 2022 🇺🇸 San Mateo, California, United States

in LinkedIn

2024Principal Scientist· Gilead Sciences

Founder · since 2000

Company

Gilead Sciences

Role

Principal Scientist

current

Stage

—

no public source

Raised

—

no public source

Based

San Francisco Bay Area

current

Founder / co-founder — the company's markEmployee / research role

Source: LinkedIn work history

Profile coverage5 of 7 · missing posts, contact

Eugit Therapeutics

Enabling Tissue Targeting of Therapies

Summer 2022

Experience

Career

Gilead Sciences
Principal Scientist · San Francisco Bay Area · 2024 – Present
2024
Eugit Therapeutics
Co-founder
Co-Founder · San Francisco Bay Area · 2022 – Present
2022
23andMe
Senior Scientist · South San Francisco, California · 2020 – 2022
2020
The University of Edinburgh
Principal Investigator/Senior Lecturer · Edinburgh, United Kingdom · 2016 – 2020
2016
University of Toronto
Assistant Professor · Toronto, Ontario, Canada · 2011 – 2016
2011
Ontario Institute for Cancer Research
Principal Investigator · Toronto, Canada Area · 2008 – 2015
2008
Harvard Medical School
Postdoctoral Fellow (George Church lab) · Boston, Massachusetts · 2007 – 2008
2007
University of Toronto
Postdoctoral Fellow · Toronto, Ontario, Canada · 2004 – 2007
2004
JabRef
Co-founder
Co-Founder and Lead Developer · Stanford, California, United States · 2000 – 2003
2000

Bio

Nizar is the co-founder and CEO at EUGIT, which he started with George Church in 2022. He is an expert in cancer research, genomics and bioinformatics and has published over 25 articles in peer-reviewed journals such as Nature and has obtained nationally competitive grants. Prior to EUGIT, he was a scientist at 23andMe and a tenure track lecturer at the University of Edinburgh, UK. Nizar grew up in Toronto and obtained his PhD in Biophysics from Stanford.